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E-mail address: parkic@kcch.re.kr (I.-C. Park).SP600125 (SAPK Inhibitor II) is reported to function as a reversible ATP competitive inhibitor of c-
Jun N-terminal kinase (JNK). In the present study, we show that SP600125 induces a dose-dependent
decrease in mTOR activity, as assessed by reduced phosphorylation of the downstream targets S6K1
and S6, and a signiﬁcant increase in the expression of Redd1. Knockdown of Redd1 expression by
siRNA resulted in a recovery of decreased S6 phosphorylation by SP600125. Overexpression of
ATF4 upregulated the expression of Redd1, while suppression of ATF4 expression by siRNA enhanced
the level of S6 phosphorylation by downregulating the SP600125-induced increase in Redd1 expres-
sion. Together, these results indicate that SP600125 inhibits mTOR activity via an ATF4-induced
increase in Redd1 expression.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mammalian target of rapamycin (mTOR), a serine/threonine
kinase, is a downstream mediator in the phosphatidylinositol 3-
kinase/Akt signaling pathway, which plays a central regulatory role
in protein synthesis, cell proliferation, cell cycle progression, and
cell survival [1–4]. mTOR regulates cell growth through its down-
stream effectors, including the translation regulators 4E-BP1
(eukaryotic translation initiation factor 4E binding protein 1) and
S6K (ribosomal S6 kinase) [1–4]. mTOR phosphorylates S6K, which
in turn phosphorylates S6 (ribosomal protein S6) leading to an in-
crease in the translation of mRNA containing 50-terminal oligopyr-
imidine sequences [5].
Redd1 was originally isolated as an HIF-1 (hypoxia-inducible
factor-1)-responsive gene in response to hypoxia [6]. Speciﬁcally,
the transcription of Redd1 is induced by activation of HIF-1 alpha
and Sp1 under conditions of hypoxia and high cell density [7]. Sev-
eral recent reports suggest that Redd1 plays a role in the TSC1/
TSC2-mediated inhibition of mTOR under conditions of hypoxia
and energy stress [8–11]. Overexpression of Redd1 causes markedchemical Societies. Published by Einhibition of mTOR activity, while genetic loss of Redd1 leads to a
profound failure in the appropriate downregulation of mTOR activ-
ity in response to hypoxia [9].
Recently, c-Jun N-terminal kinase (JNK) was reported as a suit-
able target for protection against obesity and diabetes and that
JNK can act as a tumor suppressor [12]. Current research efforts
are focused on the development of chemical inhibitors of up-
stream kinases of JNKs and JNK. SP600125 (anthra[1,9-cd]pyra-
zol-6(2H)-one1,9-pyrazoloanthrone, SAPK Inhibitor II), is a
potent, cell-permeable, selective, and reversible inhibitor of JNK.
The inhibition by SP600125 is competitive with respect to ATP,
and SP600125 is over 300-fold more selective for JNK compared
to the ERK and p38 MAPK protein kinases [13]. The use of
SP600125 has been increasingly popular to study the role of the
JNK signaling pathways [12]. However, the recent ﬁnding reveals
that SP600125 is non-speciﬁc inhibitor of many protein kinases
with similar or greater potency than JNK [14]. Specially,
SP600125 (10 lM) inhibited S6K1 (a downstream effector of
mTOR) by 22% and JNK/SAPK by 38%. A novel ﬁnding in the pres-
ent study was the inhibition of mTOR activity by SP600125 via
ATF4-induced Redd1 expression in a JNK-independent manner.
By comparison, PD98059 and SB203580, selective inhibitors of
MEK and p38 MAPK, respectively, had no effect on ATF4/Redd1
expression or mTOR activity.lsevier B.V. All rights reserved.
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Fig. 1. SP600125 inhibits mTOR activity. H1299 cells were treated with the
indicated concentrations of SP600125, PD98059, or SB203580 for 6 h. The indicated
protein levels were measured by Western blot analysis.
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2.1. Cell culture and reagents
H1299 and HeLa cells were purchased from the American Type
Culture Collection (Manassas, VA) and cultured in the recom-
mended growth media (Invitrogen, Carlsbad, CA) in a 5% CO2 atmo-
sphere at 37 C. SP500125, PD98059, and SB203580were purchased
from Calbiochem (San Diego, CA). The antibody against Redd1 was
obtained from the ProteinTech Group (Chicago, IL), while those
against p-S6K (Thr389), S6K, p-S6 (Ser240/244), S6, and 4E-BP1
were from Cell Signaling Technology (Beverly, MA). Anti-ATF4 anti-
body was acquired from Santa Cruz Biotechnology (Santa Cruz, CA).
2.2. Isolation of RNA and RT-PCR analysis
Isolation of RNA and RT-PCR were carried out as described pre-
viously [15]. Ampliﬁcations were performed as follows: initial
denaturation at 95 C for 2 min followed by an appropriate number
of cycles of 95 C for 30 s, 55 C for 30 s, and 72 C for 30 s. The spe-
ciﬁc primers used were: Redd1 (50-GAACTCCCACCCCAGATCGG-30
and 50-CGAGGGTCAGCTGGAAGGTG-30; 468 bp product), C/EBP
homologous transcription factor (CHOP) (50-CAGACTGATCCAACTG-
CAG-30 and 50-GACTGGAATCTGGAGAGTG-30; 281 bp product), glu-
cose-regulated protein 78 (GRP78) (50-GACCTGGTACTGCTTGATG-
30 and 50-CAGGTGTCAGGCGATTCTG; 370 bp product) and b-actin
(50-GGATTCCTATGTGGGCGACAG-30 and 50-CGCTCGGTGAGGATC-
TTCATG-30; 438 bp product). The PCR products were visualized
after electrophoresis in 1.5% agarose gels by ethidium bromide.
2.3. Transient transfection assays
Expression plasmids encoding mouse wild-type and dominant-
negative mutant ATF4 (pEF/mATF4-myc and pEF/mATF4DRK-
myc) were kindly provided by Alam and coworkers [16]. The dom-
inant-negative mutant mouse ATF4 contains a six amino acid
substitution in the DNA binding domain (292RYRQKKR298 to
292GYLEAAA298). ATF4 and silencer negative control siRNA were
purchased from Ambion (Austin, TX). Transfections with plasmids
and siRNA were performed using Lipofectamine PlusTM and Lipofect-
amineTM 2000, respectively, according to the manufacturer’s instruc-
tions (Invitrogen).
2.4. Western blot analysis
Cells were washed with ice-cold PBS, and then lysed in lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% so-
dium deoxycholate, 0.1% SDS) supplemented with protease inhib-
itor cocktail (Roche, Mannheim, Germany). Insoluble components
were removed from lysates by centrifugation at 12000  g for
15 min, and the protein concentrations were determined by the
Bradford method. Protein samples (20–40 lg) were separated by
SDS–PAGE (10–14% acrylamide), and transferred to nitrocellulose
membranes. Membranes were incubated with primary antibodies,
followed by incubation with horseradish peroxidase-conjugated
secondary antibodies. Immunoreactive bands were visualized with
ECL reagents (Amersham Pharmacia, Uppsala, Sweden).β -actin
Fig. 2. SP600125-induced Redd1 expression inhibits mTOR activity. (A) H1299 cells
were treated with the indicated concentrations of SP600125, PD98059, or SB203580
for 6 h. (B) H1299 cells were transfected with Redd1 or silencer negative control
(CTL) siRNAs for 24 h, followed by 30 lM SP600125 for 6 h. Cell lysates were
prepared, and the indicated protein levels were measured by Western blot analysis.
Total RNA was isolated and RT-PCR analyses were carried out using primer pairs
speciﬁc for Redd1.3. Results and discussion
3.1. SP600125 inhibits mTOR activity
We examined the effect of SP600125, PD98059, and SB203580
(well-known JNK, MEK, and p38 MAPK inhibitors, respectively)
on mTOR activation in H1299 non-small cell lung cancer cells.Unexpectedly, SP600125 repressed mTOR signaling in a dose-
dependent manner (Fig. 1). This is evidenced by the disappearance
of phosphorylated S6K, and the appearance of a third, faster-
migrating 4E-BP1 band which corresponds to the a 4E-BP1 phos-
phorylation form [11]. Also, SP600125 inhibited phosphorylation
of S6, downstream effector of S6K. In contrast, PD98059 and
SB203580 had no a signiﬁcant effect on the phosphorylation levels
of S6K, S6, and 4E-BP1 (Fig. 1). These results suggest that SP600125
inhibits mTOR activity.
3.2. SP600125-induced Redd1 expression inhibits mTOR activity
Redd1 suppresses mTOR activity by releasing TSC2 from its
growth factor-induced association with inhibitory 14-3-3 proteins
[10]. Endogenous Redd1 is required for both dissociation of endo-
genous TSC2/14-3-3 and inhibition of mTOR [10]. Therefore, to test
the involvement of Redd1 in SP600125-induced inhibition of
mTOR activation, we examined Redd1 expression in H1299 cells
after treatment with SP600125. As shown in Fig. 2A, SP600125
induced Redd1 mRNA and protein expression in H1299 cells,
whereas PD98059 and SB203580 had no effect on Redd1 expres-
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expression suppresses mTOR activity, we examined the effects of
Redd1 downregulation on mTOR activity. Inhibition of mTOR activ-
ity is evidenced as assessed by decrease in phosphorylated S6,
downstream effector of mTOR substrate, S6K. We found that treat-
ment of H1299 cells with Redd1 speciﬁc siRNA reversed the
SP600125-induced decrease in S6 phosphorylation (Fig. 2B). These
results demonstrate that SP600125-induced inhibition of mTOR
activity is mediated by induction of Redd1 expression.
3.3. ATF4 is required for inhibition of mTOR activity mediated by
Redd1 in response to SP600125
Since ATF4 is involved in cell growth inhibition and cell death
under stress conditions such as oxidative stress or endoplasmic-
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Fig. 3. ATF4 is required for Redd1-induced inhibition of mTOR in response to SP600125. (
6 h (A) and treated with 30 lM SP600125 for the indicated times (B). (C) H1299 cells w
(ATF4 WT) or myc-tagged mATF4DN (ATF4 DN) for 24 h. (D) H1299 and HeLa cells were t
30 lM SP600125 for 6 h. The indicated protein and mRNA levels were measured by Wereticulum (ER) responses [17,18], we next investigated whether
ATF4 is induced by SP600125. As shown in Fig. 3A, we found that
SP600125 induced ATF4 protein expression as well as CHOP and
GRP78, markers of ER stress as judged by Western blot analysis
or RT-PCR. The increased levels of ATF4 and Redd1 protein were
detected at 60 min following 30 lM SP600125, at which time we
observed the decreased level of phosphorylated S6, downstream
effector of mTOR substrate, S6K (Fig. 3B). To examine the role of
ATF4 in the upregulation of Redd1 expression, we examined Redd1
expression in H1299 cells transiently transfected with plasmids
encoding Myc-ATF4 and Myc-dominant-negative ATF4. As shown
in Fig. 3C, there was an increase in Redd1 mRNA and protein levels
in H1299 cells expressing Myc-ATF4 compared with cells express-
ing dominant-negative ATF4. These results indicate that ATF4 can
upregulate expression of Redd1 without involvement of otheractin
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ransfected with ATF4 or silencer negative control (CTL) siRNAs for 24 h, followed by
stern blot analysis and RT-PCR.
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of ATF4 is responsible for the upregulation of Redd1 expression
and inhibition of mTOR activity in response to SP600125. As shown
in Fig. 3D, H1299 and HeLa cells transfected with ATF4 siRNA
almost completely blocked the upregulation of Redd1 expression
induced by SP600125. Moreover, decreased levels of phosphory-
lated S6 were recovered from cells transfected with ATF4 siRNA
after treatment with SP600125. These results indicate that ATF4
is required for inhibition of mTOR activity mediated by Redd1
expression in response to SP600125 treatment.
3.4. SP600125 acts on mTOR independent of MAPKs
To determine whether MAPKs are involved in the inhibition of
mTOR activity by SP600125, we examined the induction of ATF4/
Redd1 and mTOR activity in H1299 cells transiently transfected
with siRNAs speciﬁc for JNK1/2, ERK1/2, and p38 MAPK. As shown
in Fig. 4, the phosphorylation level of S6 (downstream effector of
mTOR substrate, S6K) did not decrease in cells transfected with
siRNAs speciﬁc for JNK1/2, ERK1/2, and p38 MAPK compared with
cells treated with homocysteine, ATF4 inducer. These results sug-
gest that MAPKs, including JNK, are not involved in the inhibition
of mTOR activity following SP600125.
3.5. Concluding remarks
Our study includes the following ﬁndings. (1) SP600125 inhib-
ited mTOR activity. (2) Redd1 expression was induced by
SP600125 and plays an important role in SP600125-induced inhi-
bition of mTOR activity. (3) ATF4 was activated by SP600125 and
was required for Redd1 expression and inhibition of mTOR in re-
sponse to SP600125. (4) MAPKs were not involved in ATF4/
Redd1-induced inhibition of mTOR activity by SP600125. Redd1
was originally isolated as an HIF-1 response gene and is also a tran-
scriptional target of p63 and p53 in the cellular response to DNA
damage. ATF-4 is a signal-responsive member of the basic leucine
zipper family of transcription factors and binds to the cAMP re-
sponse element. ATF-4 is induced by hypoxia [19], amino acid deﬁ-
ciency [20], and ER stress [21]. ATF4 protein levels increase in
response to ER stressors that cause global protein synthesis to be
diminished [21]. In the present study, we found that ATF4 overex-
pression increased Redd1 expression and that ATF4 siRNA dimin-β-actin
p-S6
ATF4
Redd1
JNK1/2
ERK1/2
p38
CT
L
siJ
NK
1/2
sip
38
siC
TL
siE
RK
1/2
Hc
y
Fig. 4. MAPKs are not involved in the inhibition of mTOR activity by SP600125.
H1299 cells were transfected with JNK1/2, ERK1/2, p38, or silencer negative control
(CTL) siRNAs for 24 h. As an addition control, H1299 cells were treated with 2.5 mM
DL-homocysteine (Hcy) for 6 h. The indicated protein levels were measured by
Western blot analysis.ished SP600125-induced Redd1 expression. Together, these
results suggest that Redd1 is a target gene of ATF4 in response to
SP600125. In addition, SP600125 has the capacity to induce ER
stress genes such as GRP78 and CHOP, which are widely used
markers of ER stress [21–24] (Fig. 3A), thus suggesting that
SP600125 is an ER stressor. SP600125 has been increasingly popu-
lar in studies of the contributions to the JNK pathways [10]. How-
ever, this compound can inhibit other protein kinases including
SGK, S6K1, AMPK, CDK2, CK1d, and DYRK1A [14]. Our ﬁndings
show that SP600125 can inhibit mTOR activity via ATF4-induced
Redd1 expression in a JNK-independent manner. These issues
should be taken into consideration when SP600125 is used to
investigate the mechanisms underlying a range of experimental
models.
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